Inhibition of Complement Pathway in Brain Injury
Author Information
Author(s): Iris Leinhase, Michal Rozanski, Denise Harhausen, Joshua M. Thurman, Oliver I. Schmidt, Amir M. Hossini, Mohy E. Taha, Daniel Rittirsch, Peter A. Ward, V. Michael Holers, Wolfgang Ertel, Philip F. Stahel
Primary Institution: Charité University Medical School, Berlin, Germany
Hypothesis
Can a monoclonal anti-factor B antibody inhibit the alternative complement activation pathway and reduce neuroinflammation after traumatic brain injury in mice?
Conclusion
The study suggests that inhibiting the alternative complement pathway with a specific antibody can reduce neuroinflammation and neuronal cell death after brain injury.
Supporting Evidence
- The mAb 1379 significantly reduced C5a levels in serum after TBI.
- Histological analysis showed less neuronal cell death in mAb 1379-treated mice.
- The study demonstrated a significant upregulation of neuroprotective genes in the injured brain.
Takeaway
This study shows that a special medicine can help protect the brain after an injury by stopping some bad reactions that happen in the body.
Methodology
Mice were given either a monoclonal anti-factor B antibody or a placebo after a traumatic brain injury, and their neurological function and brain tissue were analyzed over a week.
Potential Biases
Potential bias in treatment allocation and assessment of neurological outcomes.
Limitations
The study did not show significant neurological improvement despite neuroprotection at the tissue level.
Participant Demographics
Adult male C57BL/6 mice.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website